Floatz logo

Precemtabart Tocentecan

Non-Small Cell Lung Cancer (NSCLC)

EMD Serono Research & Development Institute, Inc.antibody_drug_conjugatePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

1205 Active assets in the Non-Small Cell Lung Cancer (NSCLC) cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

Precemtabart Tocentecan is also rated in:

colorectal cancerDormant
CCC
Indicative ·
52 / 100
View asset →
neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →